You are welcome to try out the new site at https://beta.valueresearchonline.com
Small is beautiful in pharma
With high numbers of ANDAs, mid-rung pharma companies could outperform their larger peers in the future
By Mohammed Ekramul Haque | Dec 10, 2015
The pharmaceutical sector has had a successful run for quite some time in the markets. A strengthening ANDA (acronym for Abbreviated New Drug Application; an application for generic drug approval in the US) portfolio and higher earnings growth visibility have been the main boosters for the pharma sector's outperformance.
Big pharma companies, like Sun Pharma, Lupin, Dr. Reddy's, have been in high demand and are market favourites. High earnings visibility and secular earnings growth meant that large-cap pharma stocks were preferred over their mid-rung peers. This has taken valuations of large-cap pharma stocks to heated levels.
On the other hand, the often-ignored mid-rung pharma stocks have been chugging along, increasing their earnings visibility with a steady build-up of their ANDA portfolios. A spate of mid-rung pharma companies, in recent times, has seen a higher rate of ANDA approvals as compared to their larger peers. Aurobindo Pharma tops the list of highest ANDA approvals among Indian firms in the first half of this calendar year, with 19 approvals so far. Almebic Pharma is third in the list of highest ANDA approvals this year (behind Lupin) with nine approvals, followed by eight of Glenmark (see the chart below).
Even cumulatively, mid-rung pharma companies are racing ahead with higher number of ANDA filings - even ahead of larger players. Aurobindo Pharma again tops the list with a pipeline of 178 ANDAs followed by Cadila's 165 (see the second chart below).
Another advantage going mid-rung pharma companies' way is valuations. S&P BSE Healthcare index trades at 43 times earnings. Large-cap pharma stocks too trade in a similar range. In contrast, Aurobindo Pharma trades at 30.5 times earnings, Cadila at 32 times earnings and Torrent at 28 times earnings. This begs the question: is it the time for mid-rung pharma stocks to take the lead?
Are you missing an opportunity to invest in great stocks at low valuations? There are thousands of listed companies in India and yet only a handful that are worth investing at a particular time and at a particular price.
Our equity team has sifted through hundreds of companies and selected stocks that you should invest in. This list now has 37 stocks on it, and new ones are being added every month. Thousands of our members are using stagnant equity markets to buy great stocks at low prices. Membership of Value Research Stock Advisor is available at a 40% to 60% discount. Learn more and become a member